Symbollon Pharmaceuticals, Inc.: Symbollon Pharmaceuticals Announces Third Quarter 2006 Results
15th Nov 2006, 01:48 GMT
FRAMINGHAM, MA (MARKET WIRE) Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) today announced financial results for the third quarter ended September 30, 2006. For the three months ended September 30, 2006, the Company reported a net loss of $663,043, or a diluted loss per share of $0.07, compared with a net income of $38,395, or a diluted income per share of $0.00 in the prior year. For the nine months ended September 30, 2006,
Symbollon Pharmaceuticals, Inc.: Symbollon Pharmaceuticals Announces Third Quarter 2006 Results related news:
- Ligand Pharmaceuticals Announces Conference Call on Third Quarter Financial Results — RedOrbit News - Health
- Ambrilia Biopharma Inc.: Ambrilia Announces Third Quarter 2006 Results and Provides Update on Lead Development Programs — Market Wire - Pharmaceuticals and Biotech
- CPAC, Inc.: CPAC, Inc. Announces Strong Second Quarter and Six-Month Results; Declares Dividend — Market Wire - Lifestyle and Leisure
- Flexible Solutions International, Inc.: FLEXIBLE SOLUTIONS Announces Third Quarter, 2006 Financial Results — Market Wire - Energy and Utilities
- Jaclyn Reports First Quarter Financial Results; Announces Developments Concerning Purchase Option on West New York Facility — ArriveNet : Press Releases
- Inflazyme Pharmaceuticals Ltd.: Inflazyme Pharmaceuticals Ltd.: Shareholder Letter and Financial Results for the Quarter Ended September 30, 2006 — Market Wire - Pharmaceuticals and Biotech
- Computer Software Innovations, Inc. Announces Third Quarter 2006 Financial Results Conference Call — VoIP
- ProMetic Life Sciences Inc.: ProMetic Reports on Business Highlights and on Financial Results for its Third Quarter 2006 — Market Wire - Pharmaceuticals and Biotech
- PriceSmart, Inc.: PriceSmart Announces Fourth Quarter and Fiscal Year Results of Operation — Market Wire - Retail
- Idera Pharmaceuticals Announces Financial Results for the 3 and 9 Months Ended 9/30/2006 — Operations-Related News from StratCenter.com
Latest news from Market Wire - Pharmaceuticals and Biotech:
- Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
- Crucell N.V.: Crucell Announces Third Quarter 2006 Results
- Acambis PLC: Acambis PLC announces Update on US MVA procurement
- SkyePharma PLC: SkyePharma PLC announces Board Appointment
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech